Trial · NCT05254808
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to recovery | 28 days | Duration of absence of cystitis symptoms is defined as 'the number of days with full resolution of relevant cystitis symptoms, in the absence of aggravation to pyelonephritis or urosepsis within the period of 28 days after randomisation' |
| Secondary | Clinical failure | 28 days | Rate of clinical failure, defined as new or persisting cystitis symptoms or aggravation to pyelonephritis or urosepsis for which a new antibiotic treatment was prescribed within 28 days |
| Secondary | Microbiological failure | 28 days | Rate of microbiological failure at day 28 (26 to 31) defined as persistence of the initial infecting organism (≥ 103 colony forming units (cfu) /ml) |
| Secondary | Development of pyelonephritis or urosepsis | 28 days | Rate of pyelonephritis or urosepsis, defined as the occurrence of signs or symptoms of pyelonephritis or urosepsis (fever, flank pain, or other matching symptoms) for which antibiotic treatment was prescribed\* |
| Secondary | Relapse | 28 days | Rate of relapses at day 28, defined as clinical failure caused by the initial infecting organism (\> 103 cfu /ml) |
| Secondary | Reinfection | 28 days | Rate of reinfections at day 28, defined as clinical failure caused by another organism than the initial infecting organism |
| Secondary | All-cause mortality | 28 days | Rate of mortality (all-cause) |
| Secondary | All-cause hospital admission | 28 days | Rate of hospital admission (all-cause) |
| Secondary | Adverse events symptoms | 28 days | Duration of adverse events symptoms (including diarrhea, nausea, abdominal cramps, increased vaginal discharge or other). |
| Secondary | Incidence and nature of severe adverse events | 28 days | |
| Secondary | Therapy adherence | 7 days | Rate of complete self-reported therapy adherence |
| Secondary | Satisfaction with treatment | 28 days | Satisfaction with the treatment received on a scale of 5. A scale from 1 to 5 will be calculated for each comparison and will be reported with corresponding 98.3% confidence intervals. |
| Secondary | Absenteeism education or work | 28 days | Number of days of absenteeism: * education * (voluntary) work |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05254808/registered